The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Here's some further extracts from David Smith's 18.9.18 video interview on Proactive Investors, also from the part where he's talking about IB's IB Neuro brain tumour scanning software:
Q. "… you're moving towards a click fee cloud-based model here are you?"
D.S. "That's right. This technology has been available for the last six or seven years, and it has been used by some of the largest institutions in the US. For example the Mayo Clinic uses our software. What we're doing is we'd like to make that available to really any hospital that has an internet connection. And the way that we do that is rather than having this large piece of software that is somewhat static because it's not updated that frequently. What we would like to do is make that software available on a click fee basis. Every time a patient has a scan, give doctors the opportunity to access this very powerful software product on a per patient basis or a per click basis. And often times, a patient will need that interpretative software used on their brain scan many times, not just for the initial appointment, but also for appointments around the surgery time, and then follow-up appointments to make sure that the surgery was successful."
Q. "And you're in the process now of securing a number of patents around the AI for this are you?"
D.S. "Around both artificial intelligence associated with the software, and for software developments themselves to make the software even more effective. And the main benefit of artificial intelligence is, as you can imagine with a click fee, every time the doctor accesses our software, we get anonymous patient information. But by putting all of that together, and knowing whether ultimately that patient did have cancer at the point we predicted they would, we can actually improve that product. So over time doctors are getting a more powerful product in terms of their diagnostic capability, and they're getting it without having to make a huge financial investment, and that's something that they might have to plan for over two or three years as they put their capital budgets together. This way they can do it more or less immediately and bring that benefit to patients immediately."
Here's an extract from David Smith's 18.9.18 video interview on Proactive Investors, from the part where he's talking about IB's IB Neuro brain tumour scanning software:
Q. "Give us a quick recap, firstly on Imaging Biometrics, the flagship product here IB Neuro. And how this works."
D.S. "Well IB Neuro is an interpretative software for brain scans. So you never want to be on the end of an IB Neuro software output, because it means you likely have a brain tumour. So, what happens with brain tumours is, as you're aware they're treated with radiotherapy, and more recently with proton therapy, and often times if they're either surgically removed or treated with this radiation therapy you can end up with a scar, instead of the tumour. But under existing software products that scar appears exactly the same as the tumour. So when you go for your follow-up appointment, and you have your scan, and software is used to look at that brain tumour to see if the surgeon got all of it, what you actually find is that it appears to be new tumour growth, it's something we call pseudoprogression; it's not real tumour growth, it's scar tissue. And that can result in surgeons going back in, erroneously, and trying to remove more tumour that doesn't exist. Or sometimes if you're on a chemotherapy regimen, what happens is you take the chemotherapy drugs, and it appears that they're not working, when they really are working. So in that case the chemotherapy would be stopped, again in error. So what our software does is it looks at the perfusion of blood, the flow of blood, through the tumour. If there's healthy blood flow, it's likely that that's active tumour. But if we look at those areas that look indistinguishable on the scan under regular software, with our software you can actually see the blood flowing, and then you know it's active tumour."
Thanks Rubbermanneke.
I think that a market cap. of below £10M. is a steal here, considering the valuations of IQAI's listed peers.
Currently just £9M., at 6.4p, it's under a third of the market cap. of Polarean Imaging (POLX) (£29M. at 25p), which is itself seen as very undervalued, and has been suffering from an overhang.
Much imaging technology in use is woefully outdated, and there is massive scope for improvement, giving a massive opportunity for imaging players like IQAI and POLX.
Indeed, imaging could potentially be one of the 'next big things' in investment, and IQAI looks like a superb way to ride this wave.
Thanks Hedge! Appreciate your posts! Ready for 8p target tomorrow...
A reminder of Imaging Biometrics' recent clinical trials success with its dT1 brain tumour scanning software (which wasn't actually RNSed).
These are the most key points:
"CONCLUSIONS: This study shows that dT1 can predict early progression comparable with the standard method but offers the potential for substantial time and cost savings for clinical trials."
"Consequently, the dT1 tool has the potential to cause a paradigm shift in how brain tumor burden is assessed."
http://www.ajnr.org/content/40/7/1132
And the dT1 tool is one of IQAI's projects that will be accelerated with the new 6th. August 2019 placing funds:
"The funds raised will be used to accelerate the commercialisation and development of two of Imaging Biometric's ("IB") projects: the low-flip angle technique; and IB's Delta T1 mapping approach."
https://www.lse.co.uk/rns/IQAI/iq-ai-limited-placing--mij57v9jf1bxqgz.html
In fact, David Smith has said (in an investor lunch last August) that whilst StoneChecker software has great potential, the real winner could be the brain scanning software of IB, which should be extended to other areas. Liver was mentioned as achievable with minor tweaks.
Considering the immense potential for StoneChecker software, this is really saying something.
A look at the Imaging Biometrics website shows how outstanding their technology is.
https://www.imagingbiometrics.com/
Indeed IQAI is a technology leader.
It's groundbreaking products are disruptive technology at its finest, offering improved performance and big savings.
And the high technological and other barriers to entry make it difficult to compete against.
Allied to the brilliant business and sales nous of Trevor Brown and David Smith, and it's the perfect combination for a tip top growth stock.
"Global Brain Tumor Diagnosis and Treatment Market Worth Over USD 744 Million by 2024: Zion Market Research
According to the report, the global brain tumor diagnosis and treatment market was valued at approximately USD 426 million in 2017 and is expected to generate revenue of around USD 744 million by the end of 2024, growing at a CAGR of around 8.65% between 2018 and 2024.
October 29, 2018 01:48 ET | Source: Zion Market Research
... Brain tumors generally occur in supportive brain tissues. The exact cause of brain tumor is not yet known, and it can occur in any age group. Neurologists base the brain tumor treatment on the type, tumor location, tumor size, patient’s health, and patient’s age. The main drivers that fuel the growth of brain tumor diagnosis and treatment market are an increase in the occurrences of brain tumor, the rise in the geriatric population, and the development of technologies for tumor treatment. ...
The main players of the global brain tumor diagnosis and treatment market are AstraZeneca, GE Healthcare, Carestream Health, Pfizer, Inc., Merck & Co. Inc., Siemens Healthineers, Hitachi Medical Corporation, Philips Healthcare, Toshiba Medical Systems Corporation, and Shimadzu Corporation. These companies focus on mergers and collaborations to develop their diagnostics techniques. For instance, in 2015, NICO announced its collaboration with Hitachi Aloka Medical to improve visualization of difficult to reach brain tumors. ... "
http://www.globenewswire.com/news-release/2018/10/29/1637971/0/en/Global-Brain-Tumor-Diagnosis-and-Treatment-Market-Worth-Over-USD-744-Million-by-2024-Zion-Market-Research.html
Note that CorTech Labs, who IQAI partnered with in June, have agreements with very big players like GE Healthcare and others.
And that David Smith (in an investor lunch last August) has said that IQAI will probably later be taken out by GE or Phillips, who provide the hardware but have poor software that is 20 years old in many cases.
An IQAI joint venture with one of these large players, involving a large cash injection, could I think be a possibility.